Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Intervalo de ano de publicação
2.
Behav Brain Res ; 397: 112887, 2021 01 15.
Artigo em Inglês | MEDLINE | ID: mdl-32931838

RESUMO

Varenicline is one of the top medications used for smoking cessation and is often prescribed before termination of nicotine use. The effect of this combined nicotine and varenicline use on the reward system and motivation for primary reinforcement is underexplored. The goal of this study was to assess the effects of nicotine and varenicline on motivation for a food reinforcer. In Experiment 1, we first assessed the responding for sucrose after pretreatment with nicotine (0, 0.1, or 0.4 mg/kg) and varenicline (0.0, 0.1, 1.0 mg/kg) using a behavioral economics approach. The responding for sucrose was then assessed using a progressive ratio schedule of reinforcement after pretreatment with all possible combinations of nicotine and varenicline doses. In Experiment 2, rats were assessed for the consumption of sucrose in home cages after pretreatment with nicotine and varenicline. We found that (a) nicotine decreased economic demand for sucrose, (b) varenicline rescued nicotine-induced reduction in economic demand for sucrose, and (c) history of varenicline treatment predicted responding for sucrose on a progressive ratio schedule of reinforcement where rats with a history of varenicline treatment responded significantly lower for sucrose across nicotine doses than rats that had not been exposed to varenicline. The results of Experiment 2 largely confirmed that nicotine decreases motivation for sucrose using a passive consumption protocol and that varenicline rescues this effect. Overall, these findings suggest that varenicline interacts with the effects of nicotine by restoring nicotine-induced reduction in motivation for appetitive rewards.


Assuntos
Comportamento Alimentar/efeitos dos fármacos , Motivação/efeitos dos fármacos , Nicotina/farmacologia , Agonistas Nicotínicos/farmacologia , Reforço Psicológico , Agentes de Cessação do Hábito de Fumar/farmacologia , Sacarose/farmacologia , Vareniclina/farmacologia , Animais , Comportamento Animal/efeitos dos fármacos , Interações Medicamentosas , Economia Comportamental , Masculino , Nicotina/administração & dosagem , Agonistas Nicotínicos/administração & dosagem , Ratos , Ratos Sprague-Dawley , Esquema de Reforço , Agentes de Cessação do Hábito de Fumar/administração & dosagem , Vareniclina/administração & dosagem
3.
BMC Public Health ; 16: 543, 2016 07 11.
Artigo em Inglês | MEDLINE | ID: mdl-27401980

RESUMO

BACKGROUND: Electronic cigarettes (e-cigarettes) are popular alternatives to conventional cigarettes among adult smokers wishing to reduce their exposure to harmful smoke constituents. However, little information exists on the relative internal exposures resulting from the exclusive or dual use of e-cigarettes. METHODS: Measurements of product use; adverse events; changes in smoking urge; and blood, urine and exhaled breath biomarkers of exposure (BoE) representing toxicants believed to contribute to smoking related diseases were made at baseline and after five days of product use in 105 clinically-confined smokers randomized into groups that partially or completely substituted their usual brand combustible cigarette with commercial e-cigarettes, or discontinued all nicotine and tobacco products. RESULTS: Subjects switching to e-cigarettes had significantly lower levels (29 %-95 %) of urinary BoEs after 5 days. Nicotine equivalents declined by 25 %-40 %. Dual users who substituted half of their self-reported daily cigarette consumption with e-cigarettes experienced 7 %-38 % reductions, but had increases (1 %-20 %) in nicotine equivalents. Blood nicotine biomarker levels were lower in the cessation (75 %-96 %) and e-cigarette use groups (11 %-83 %); dual users had no significant reductions. All groups experienced significant decreases in exhaled CO (27 %-89 %). Exhaled NO increases (46 %-63 %) were observed in the cessation and e-cigarette use groups; dual users had minimal changes. By Day 5, all groups had greater reductions in smoking urge compared to cessation. However, reductions were larger in the dual use group. No serious adverse events were observed. CONCLUSIONS: Exposures to harmful smoke toxicants were observed to be lower in smokers who completely or partially replaced their cigarettes with e-cigarettes over five days.


Assuntos
Fissura , Sistemas Eletrônicos de Liberação de Nicotina/estatística & dados numéricos , Abandono do Hábito de Fumar/métodos , Fumar/metabolismo , Fumar/psicologia , Produtos do Tabaco , Adulto , Biomarcadores/metabolismo , Sistemas Eletrônicos de Liberação de Nicotina/efeitos adversos , Expiração , Feminino , Seguimentos , Substâncias Perigosas/metabolismo , Humanos , Masculino , Nicotina/metabolismo , Fumar/efeitos adversos
4.
Psychiatry Investig ; 11(3): 290-6, 2014 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-25110502

RESUMO

OBJECTIVE: The risks of cigarette smoking concerning higher systemic disease mortality are lessened by smoking cessation. METHODS: Microarray analysis compared the expression profiles of smokers who were successful and not successful at smoking cessation, with the goal of identifying genes that might serve as potential biomarkers or that might be valuable in elucidating distinct biological mechanisms. The mRNAs were isolated and compared from peripheral leukocytes of six smokers who were successful in cessation and six smokers who failed in smoking cessation. RESULTS: Two hundred ninety nine genes displayed significantly different expression; 196 genes were up-regulated and 103 genes were down-regulated in the success group compared to the failure group. Twenty four of these genes were identified with biological processes including immunity, cytoskeleton and cell growth/cycle. Real-time PCR confirmed the differential gene expression. The mRNA levels of HEPACAM family member 2 (HEPACAM2) and tropomodulin 1 (TMOD1) were significantly more expressed in the success group, while the mRNA ubiquitin specific peptides 18 (USP18) were significantly less expressed in the success group compared to the failure group. CONCLUSION: The results suggest that smoking cessation can modulate cell adhesion and immune response by regulating expression levels of genes, especially HEPACAM2, TMOD1 and USP18, which have an important relationship with smoking cessation.

5.
Adv Biomed Res ; 3: 251, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25590029

RESUMO

BACKGROUND: Nicotine as one of the potent psychostimulant drugs is characterized by its parasympathomimetic activity. Upon the abrupt discontinuation of nicotine intake, a number of symptoms such as anxiety, depression and cognition impairment develop. Kefir as a food supplement is rich in tryptophan. In this study, we have evaluated the effects of Kefir on nicotine cessation-induced anxiety, depression and cognition impairment. MATERIALS AND METHODS: Forty adult male rats were divided into four groups. All the groups received 6 mg/kg/day of nicotine for 17 days and then the negative control groups got 5 mg/kg/day of normal saline. The positive control groups were given 40 mg/kg/day of Sertraline HCl for 7 days. The group treated with Cow Milk Kefir (CMK) and Soy Milk Kefir (SMK) received 5 mg/kg/day for 7 days. On the 25(th) day, Elevated Plus Maze (EPM), Open Field Test (OFT) and Forced Swim Test (FST) were used to investigate anxiety and depression. In addition, Moris Water Maze was applied to evaluate learning and memory in the animals between the 20(th) and 25(th) days. RESULTS: The results showed that administration of CMK, SMK and Sertraline had higher anti-depression and anxiolytic effects on nicotine withdrawal-induced depression and anxiety in rats (P < 0.05). Moreover, CMK and SMK improved learning and memory impairment results in the nicotine withdrawal period (P < 0.05). CONCLUSION: This study revealed that Kefir had a potential effect on the treatment of nicotine cessation-induced depression, anxiety and cognition impairment in the animal model. Kefir may be useful for adjunct therapy for nicotine abandonment treatment protocols.

6.
Psychiatry Investigation ; : 290-296, 2014.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-174673

RESUMO

OBJECTIVE: The risks of cigarette smoking concerning higher systemic disease mortality are lessened by smoking cessation. METHODS: Microarray analysis compared the expression profiles of smokers who were successful and not successful at smoking cessation, with the goal of identifying genes that might serve as potential biomarkers or that might be valuable in elucidating distinct biological mechanisms. The mRNAs were isolated and compared from peripheral leukocytes of six smokers who were successful in cessation and six smokers who failed in smoking cessation. RESULTS: Two hundred ninety nine genes displayed significantly different expression; 196 genes were up-regulated and 103 genes were down-regulated in the success group compared to the failure group. Twenty four of these genes were identified with biological processes including immunity, cytoskeleton and cell growth/cycle. Real-time PCR confirmed the differential gene expression. The mRNA levels of HEPACAM family member 2 (HEPACAM2) and tropomodulin 1 (TMOD1) were significantly more expressed in the success group, while the mRNA ubiquitin specific peptides 18 (USP18) were significantly less expressed in the success group compared to the failure group. CONCLUSION: The results suggest that smoking cessation can modulate cell adhesion and immune response by regulating expression levels of genes, especially HEPACAM2, TMOD1 and USP18, which have an important relationship with smoking cessation.


Assuntos
Humanos , Biomarcadores , Fenômenos Biológicos , Adesão Celular , Citoesqueleto , Expressão Gênica , Leucócitos , Análise em Microsséries , Mortalidade , Peptídeos , Reação em Cadeia da Polimerase em Tempo Real , RNA Mensageiro , Fumar , Abandono do Hábito de Fumar , Tropomodulina , Ubiquitina
7.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-104512

RESUMO

OBJECTIVES: The Nicotine Dependence Syndrome Scale has been reported as valid and useful measure for assessment of the level and the pattern of nicotine dependence. The aim of this study is to prove the validity and reliability of the Korean version of Nicotine Dependence Syndrome Scale and find out its predictive effect on smoking cessation. METHODS: 274 smokers who visited the public health center smoking cessation clinic were enrolled in this study. Fagerstrom test and K-NDSS were administered and the subjects started smoking cessation after basic assessment was done with the aid of bupropion and nicotine patch. Six month later smoking cessation success or failure was assessed through self report. RESULTS: K-NDSS factor structure was very similar to the original version of NDSS and has proved to be valid and reliable. Cronbach's alpha for K-NDSS-Total was .90, and Cronbach's alpha for each sub-factors are ranged from .66 to .85. Sub-factor, continuity and stereotypy can predict the possibility of smoking cessation success or failure. CONCLUSION: K-NDSS was proved to be a valid and a reliable measure of nicotine dependence, and its sub-factor continuity and stereotypy has predictive characteristic on smoking cessation.


Assuntos
Bupropiona , Nicotina , Saúde Pública , Reprodutibilidade dos Testes , Autorrelato , Fumar , Abandono do Hábito de Fumar , Dispositivos para o Abandono do Uso de Tabaco , Tabagismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...